Oct. 23, 2009 (Business Wire) -- The Medicines Company (NASDAQ:MDCO) announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI). The basis of this approval is the landmark HORIZONS-AMI study which was the first drug trial to demonstrate a reduction in deaths from heart attacks in patients undergoing emergency PCI. The trial showed that patients treated with Angiox compared with today’s leading treatment - heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) – were more likely to survive and had less frequent severe bleeds.

Professeur Ph. Gabriel Steg, from Centre Hôpitalier Bichat in Paris, France commented that “The sustained reduction in all-cause and cardiovascular mortality achieved by bivalirudin in the context of primary PCI, compared to the standard of care, provides a compelling case for switching to bivalirudin as the preferred anticoagulant for primary PCI.”

The HORIZONS-AMI Trial

The HORIZONS-AMI trial compared Angiox to heparin plus a GPI in 3,602 patients (57 percent of whom were recruited in Europe) presenting with the most severe form of heart attack, known as STEMI, undergoing a emergency (primary) PCI.

Results at 30 days showed that Angiox:

• Significantly improved overall mortality including a reduction in the incidence of heart-related deaths by 38 percent (1.8% vs. 2.9%, p=0.03)
• Significantly reduced the incidence of major bleeding by 42 percent (5.1% vs. 8.8%, p< 0.0001).
• Significantly reduced the incidence of net adverse clinical events, a composite of major adverse cardiac events or major bleeding, by 26 percent (9.3% vs. 12.7%, p = 0.0015).
• Demonstrated comparable rates of major adverse cardiac events (5.4% vs. 5.5%, p = 0.8901).

Long terms results of the HORIZONS-AMI data have been published recently - including one-year data recently published in The Lancet, and two-year data, recently presented at the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference, confirm the 30-day mortality benefit showing a significant 38 percent reduction in cardiac mortality at 30 days, which was maintained at 43 percent (at one year) and 41 percent (at two years).

“The HORIZONS–AMI trial confirms the role of Angiox as an alternative anticoagulant strategy to treat patients with acute myocardial infarction undergoing primary PCI.